Baxter International Inc. $BAX Shares Acquired by Ameriprise Financial Inc.

Key Points

• Ameriprise Financial Inc. has increased its stake in Baxter International by 1.1%, bringing its total holdings to 7,540,942 shares, valued at $258.14 million.
• Baxter International's recent quarterly earnings missed analysts' expectations, reporting $0.59 EPS against a consensus estimate of $0.60, and revealing a revenue of $2.81 billion.
• Several brokerages have lowered their target prices for Baxter International stock, with Wells Fargo reducing it from $33.00 to $24.00 and Morgan Stanley decreasing it from $28.00 to $27.00.

Ameriprise Financial Inc. grew its holdings in Baxter International Inc. (NYSE:BAX - Free Report) by 1.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,540,942 shares of the medical instruments supplier's stock after purchasing an additional 83,973 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.47% of Baxter International worth $258,140,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BAX. ARGA Investment Management LP lifted its position in Baxter International by 52.5% during the first quarter. ARGA Investment Management LP now owns 1,327,946 shares of the medical instruments supplier's stock valued at $45,456,000 after acquiring an additional 457,345 shares during the last quarter. GAMMA Investing LLC lifted its position in Baxter International by 11,821.6% during the first quarter. GAMMA Investing LLC now owns 387,689 shares of the medical instruments supplier's stock valued at $13,271,000 after acquiring an additional 384,437 shares during the last quarter. Parkwood LLC purchased a new stake in Baxter International during the fourth quarter valued at approximately $10,747,000. Sound Shore Management Inc. CT lifted its position in Baxter International by 13.7% during the first quarter. Sound Shore Management Inc. CT now owns 2,825,902 shares of the medical instruments supplier's stock valued at $96,731,000 after acquiring an additional 341,321 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Baxter International during the first quarter valued at approximately $8,426,000. Hedge funds and other institutional investors own 90.19% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Citigroup dropped their target price on shares of Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 9th. Barclays dropped their target price on shares of Baxter International from $41.00 to $36.00 and set an "overweight" rating on the stock in a research report on Monday, August 4th. Stifel Nicolaus reaffirmed a "hold" rating and issued a $25.00 price objective (down from $36.00) on shares of Baxter International in a report on Monday, August 4th. UBS Group dropped their price objective on shares of Baxter International from $35.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Finally, Evercore ISI dropped their price objective on shares of Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Three equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $30.11.

Baxter International Price Performance

Shares of NYSE BAX traded down $0.15 during trading on Thursday, hitting $24.39. The company had a trading volume of 1,649,189 shares, compared to its average volume of 5,322,141. The stock has a fifty day simple moving average of $27.13 and a two-hundred day simple moving average of $30.04. Baxter International Inc. has a fifty-two week low of $21.33 and a fifty-two week high of $40.49. The firm has a market capitalization of $12.52 billion, a price-to-earnings ratio of -81.32, a price-to-earnings-growth ratio of 0.80 and a beta of 0.59. The company has a quick ratio of 1.49, a current ratio of 2.30 and a debt-to-equity ratio of 1.30.

Baxter International (NYSE:BAX - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The firm had revenue of $2.81 billion for the quarter, compared to analysts' expectations of $2.82 billion. During the same period last year, the firm earned $0.68 earnings per share. Baxter International's revenue for the quarter was up 4.3% on a year-over-year basis. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. On average, research analysts expect that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Friday, August 29th will be given a dividend of $0.17 per share. The ex-dividend date is Friday, August 29th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.8%. Baxter International's dividend payout ratio (DPR) is currently -226.67%.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.